Swedbank
MLYS icon

Swedbank’s Mineralys Therapeutics MLYS Stock Holding History

Swedbank’s Portfolio MLYS Stock Details MLYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-122,100
Closed -$3.31M – 712
2026
Q1 		$3.31M Sell
122,100
-99,300
-45% -$2.91M ﹤0.01% 600
2025
Q4 		$8.03M Sell
221,400
-77,900
-26% -$3.12M 0.01% 529
2025
Q3 		$11.3M Sell
299,300
-84,500
-22% -$1.83M 0.01% 469
2025
Q2 		$5.19M Buy
383,800
+56,100
+17% +$813K 0.01% 542
2025
Q1 		$5.2M Buy
+327,700
New +$3.77M 0.01% 540

Other funds holding MLYS

AP
Andera Partners Paris $206M AUM
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
AA
ALPS Advisors Denver, Colorado $21.3B AUM 23.41% 1-Year Est. Return
HWAM
Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
ACM
ACT Capital Management Wayne, Pennsylvania $153M AUM
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
New York State Common Retirement Fund
New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return
EC
Eleva Capital Paris, France $343M AUM

Swedbank's MLYS Position: Q2 2026 in Review

Swedbank sold out of Mineralys Therapeutics (MLYS) in Q2 2026, closing a stake of 122,100 shares — an estimated $3.31M sold.

Swedbank first reported a position in MLYS in Q1 2025 and held it in 5 quarters. The position peaked at $11.3M in Q3 2025. 28 funds tracked by Wall St. Rank hold MLYS as of Q2 2026.

  • Swedbank reported no remaining Mineralys Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Swedbank sold 122,100 Mineralys Therapeutics shares in Q2 2026, an estimated $3.31M.
  • Swedbank first reported a position in Mineralys Therapeutics in Q1 2025 and held it in 5 quarters.
  • Swedbank's Mineralys Therapeutics position peaked at $11.3M in Q3 2025.
  • 28 funds tracked by Wall St. Rank held Mineralys Therapeutics as of Q2 2026.

Based on Swedbank's 13F filing for Q2 2026, filed 15 Jul 2026.